Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kahsai Alem W, Pakharukova Natalia, Kwon Henry Y, Shah Kunal S, Del Real Caroline T, Shreiber Bowie N, Liang-Lin Jason G, Shim Paul J, Lee Mason A, Ngo Van A, Schwalb Allison M, Pham Uyen, Chundi Anand, Jiang Haoran, Flores-Espinoza Emmanuel, Liu Samuel, Nibley Preston C, Bassford Dana K, Hahn Hyunggu, Kunzle Cal A, Thomas Brittany N, Kim Jihee, Zhou Yang, Wang Jialu, Zhang Xingdong, Smith Jeffrey S, Rein Lindsay A M, Thomsen Alex R B, Shenoy Sudha K, Rajagopal Sudarshan, Shi Lei, Ahn Seungkirl, Rockman Howard A, Masoudi Ali, Lefkowitz Robert J
Аннотация
β-Arrestins are multifunctional regulators of G-protein-coupled receptor (GPCR) signalling and orchestrate diverse downstream signalling events and physiological responses across the GPCR superfamily1-3. Although GPCR pharmacology has advanced to target orthosteric and allosteric sites, as well as G proteins and GPCR kinases, direct chemical tools to modulate β-arrestin activities have remained conspicuously absent. Here we report the identification of small-molecule inhibitors that selectively target β-arrestins and delineate their mechanism of action through integrated pharmacological, biochemical, biophysical and structural analyses. These inhibitors disrupt β-arrestin engagement with agonist-activated GPCRs, impairing desensitization, internalization and β-arrestin-dependent physiological functions while sparing G protein-receptor coupling. Cryo-electron microscopy, molecular dynamics simulations and structure-guided mutagenesis reveal that one modulator, Cmpd-5, engages a pocket within the central crest of β-arrestin1 formed by the middle, C and lariat loops, a critical receptor-binding interface, stabilizing a distinct conformation that is incompatible with full β-arrestin-receptor engagement. Together, these findings establish a mechanistic framework for β-arrestin modulation, reveal a novel allosteric site for structure-based drug design, and open new avenues for transducer-targeted, pathway-specific GPCR therapeutic agents.